Improved drug-screening tests of candidate anti-cancer drugs in patient-derived xenografts through use of numerous measures of tumor growth determined in multiple independent laboratories

Our results showed that drug screening tests utilizing p-values from meta-analysis of numerous labs, or multiple test correction, produced median sensitivities and specificities that were always at least as high as those for the Single-Measure, Single-Lab test. This result was true for all significance levels. The 95% confidence intervals were usually greater in length for the Single-Measure, Single-Lab screening test.